Search Result

Results for "

malignant lymphoma

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Anaplastic lymphoma kinase (ALK) (1) Apoptosis (7) Aurora Kinase (1) Autophagy (2) Bcl-2 Family (1) Biochemical Assay Reagents (2) Btk (1) CD20 (4) CD3 (3) CD38 (1) DNA/RNA Synthesis (1) Drug Metabolite (1) E3 Ligase Ligand-Linker Conjugates (1) Endogenous Metabolite (1) Fc Receptor (FcR) (1) HIV (2) Isotope-Labeled Compounds (2) Melanocortin Receptor (1) Mitochondrial Metabolism (1) N-myristoyltransferase (1) P-glycoprotein (1) Phosphatase (1) PI3K (2) PROTACs (1) PTEN (2) Reference Standards (2) Sec61 (1) STAT (1) TNF Receptor (1)
By Research Areas:	Cancer (23) Infection (1) Inflammation/Immunology (7) Metabolic Disease (3) Neurological Disease (1)

By Targets:

Anaplastic lymphoma kinase (ALK) (1)

Apoptosis (7)

Aurora Kinase (1)

Autophagy (2)

Bcl-2 Family (1)

Biochemical Assay Reagents (2)

Btk (1)

CD20 (4)

CD3 (3)

CD38 (1)

DNA/RNA Synthesis (1)

Drug Metabolite (1)

E3 Ligase Ligand-Linker Conjugates (1)

Endogenous Metabolite (1)

Fc Receptor (FcR) (1)

HIV (2)

Isotope-Labeled Compounds (2)

Melanocortin Receptor (1)

Mitochondrial Metabolism (1)

N-myristoyltransferase (1)

P-glycoprotein (1)

Phosphatase (1)

PI3K (2)

PROTACs (1)

PTEN (2)

Reference Standards (2)

Sec61 (1)

STAT (1)

TNF Receptor (1)

By Research Areas:

Cancer (23)

Infection (1)

Inflammation/Immunology (7)

Metabolic Disease (3)

Neurological Disease (1)

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Anaplastic lymphoma kinase (ALK) BCL6 MALT1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99033

Mosunetuzumab 1 Publications Verification BTCT-4465A; RG-7828; RO7030816	CD20 CD3	Inflammation/Immunology Cancer
Mosunetuzumab (BTCT-4465A) is a full-length, fully humanized immunoglobulin G1 (IgG1) T-cell-dependent bispecific (TDB) antibody targeting CD20 (B cells) and CD3 (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs) .

HY-P99024

Glofitamab 1 Publications Verification RO7082859; RG-6026	CD20 CD3	Inflammation/Immunology Cancer
Glofitamab (RO7082859) is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. Glofitamab leads to T-cell activation, proliferation, and tumor cell killing upon binding to CD20 on malignant cells. Glofitamab induces durable complete remissions in relapsed or refractory B-Cell non-Hodgkin lymphoma (B-NHL) .

HY-147308

Zelenirstat 2 Publications Verification PCLX-001	N-myristoyltransferase	Cancer
Zelenirstat is an orally acitve, small-molecule, dual N-myristoyltransferase (NMT) inhibitor, with IC₅₀s of 5 nM (NMT1) and 8 nM (NMT2), respectively. Zelenirstat can induce cell apoptosis, has anti-cancer activity, inhibits early B cell receptor (BCR) signaling, and can be used to study malignant lymphoma .

HY-N1435

Oroxin B 5 Publications Verification	Apoptosis PI3K PTEN Autophagy	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Oroxin B (OB) is a BBB-permeable flavonoid isolated from traditional Chinese herbal medicine Oroxylum indicum (L.) Vent. Oroxin B (OB) possesses obvious inhibitory effect and induces early apoptosis rather than late apoptosis on liver cancer cells through upregulation of PTEN, down regulation of COX-2, VEGF, PI3K, and p-AKT. Oroxin B (OB) selectively induces tumor-suppressive ER stress in malignant lymphoma cells .

HY-176763

KZR-261	Sec61	Cancer
KZR-261 is a Sec61 translocase inhibitor. KZR-261 binds directly to the Sec61 channel, thereby inhibiting the biosynthesis of certain Sec61 substrate proteins, including oncogenic factors. KZR-261 activates the endoplasmic reticulum stress response. KZR-261 exhibits broad in vitro anticancer activity. KZR-261 shows antitumor efficacy in mouse models of cancer. KZR-261 can be used for the research of multiple myeloma, colorectal cancer, small cell lung cancer, pancreatic cancer, prostate cancer, non-Hodgkin's lymphoma, and mantle cell lymphoma .

HY-W017194

2-Phenylbutanoic acid	Biochemical Assay Reagents HIV	Infection Cancer
2-Phenylbutanoic acid is a monocarboxylic acid. 2-Phenylbutanoic acid interacts with proteins. 2-Phenylbutanoic acid is used in the study of malignant lymphoma and HIV virus-related diseases .

HY-P991225

BI-1206	Fc Receptor (FcR) CD20	Inflammation/Immunology Cancer
BI-1206 is a recombinant and antagonistic human monoclonal antibody targeting FcγRIIB (CD32B). BI-1206 can block CD20 internalization induced by Rituximab (HY-P9913) itself or combined with others including Ibrutinib (HY-10997), Venetoclax (HY-15531), and CHOP. BI-1206 can enhance or recover the activity of Rituximab or other anti-CD20 monoclonal antibodies. BI-1206 has cytolytic activity against malignant B cells. BI-1206 can be studied for cancer research such as mantle cell lymphoma (MCL) .

HY-136268

AQX-435	Phosphatase Apoptosis	Inflammation/Immunology
AQX-435 is a potent SHIP1 phosphatase activator. AQX-435 reduces PI3K activation downstream of the B-cell receptor (BCR) and induces apoptosis of malignant B cells, and reduces lymphoma growth .

HY-105130

Menogaril	DNA/RNA Synthesis	Cancer
Menogaril is a potent and orally active anthracycline antitumor agent. Menogaril is ready penetration into cancer cells can cleave double-stranded DNA. Menogaril can be used for the research of cancer, such as malignant lymphoma .

HY-P99660

Imvotamab IGM-2323	CD20 CD3	Inflammation/Immunology Cancer
Imvotamab (IGM-2323) is a CD20 and CD3 bispecific IGM antibody with dual action mechanism. Imvotamab is used to induce physiological T cell activation to prevent over-stimulation and subsequent down-regulation of immune function. Imvotamab can be used for the study of B-cell malignant tumors, multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL) .

HY-175982

AURKA-IN-3	Aurora Kinase	Cancer
AURKA-IN-3 (Compound AL8) is an irreversible covalent Aurora kinase A (AURKA) inhibitor with an IC₅₀ value of 23.0 nM. AURKA-IN-3 inhibits the activation of cAMP signaling pathway and phospholipase C (PLC) signaling pathway mediated by AURKA, and reduces the autophosphorylation level of AURKA. AURKA-IN-3 is promising for research of malignant tumors associated with high AURKA expression (e.g., leukemia, lymphoma) .

HY-N1435R

Oroxin B (Standard)	Reference Standards Apoptosis PI3K PTEN Autophagy	Metabolic Disease Inflammation/Immunology Cancer
Oroxin B (Standard) is the analytical standard of Oroxin B. This product is intended for research and analytical applications. Oroxin B (OB) is a flavonoid isolated from traditional Chinese herbal medicine Oroxylum indicum (L.) Vent. Oroxin B (OB) possesses obvious inhibitory effect and induces early apoptosis rather than late apoptosis on liver cancer cells through upregulation of PTEN, down regulation of COX-2, VEGF, PI3K, and p-AKT . Oroxin B (OB) selectively induces tumor-suppressive ER stress in malignant lymphoma cells .

HY-N1830

3-Epiwilsonine	Others	Cancer
3-Epiwilsonine is an alkaloid from Cephalotaxus wilsoniana, exhibits effect on acute and chronic myeloid leukemia and malignant lymphoma .

HY-168298

Lenalidomide-6-F-piperidine-C2-Pip-C-COOH	E3 Ligase Ligand-Linker Conjugates	Cancer
Lenalidomide-6-F-piperidine-C2-Pip-C-COOH is a linker and E3 ligase ligand for PROTAC BTK Degrader-5 (HY-155072) and can be used in malignant lymphoma research .

HY-W017194R

2-Phenylbutanoic acid (Standard)	Reference Standards Endogenous Metabolite	Metabolic Disease
2-Phenylbutanoic acid (Standard) is the analytical standard of 2-Phenylbutanoic acid. This product is intended for research and analytical applications. 2-Phenylbutanoic acid is a monocarboxylic acid. 2-Phenylbutanoic acid interacts with proteins. 2-Phenylbutanoic acid is used in the study of malignant lymphoma and HIV virus-related diseases 。

HY-120075

TJ191	Apoptosis	Cancer
TJ191 is a potent and specific anti-cancer agent that targets low TβRIII-expressing malignant T-cell leukemia/lymphoma cells. TJ191 has no affects on the proliferation of other cancer cells or normal fibroblasts or immune cells. TJ191 can be used for cancer research .

HY-W017194S

2-Phenylbutyric acid-d5	Isotope-Labeled Compounds HIV Biochemical Assay Reagents	Cancer
2-Phenylbutyric acid-d₅ is the deuterium labeled 2-Phenylbutanoic acid (HY-W017194). 2-Phenylbutanoic acid is a monocarboxylic acid. 2-Phenylbutanoic acid interacts with proteins. 2-Phenylbutanoic acid is used in the study of malignant lymphoma and HIV virus-related diseases .

HY-110113

CTA056	Btk	Cancer
CTA056 is an ITK (IL-2-inducible T-cell kinase) inhibitor with an IC₅₀ of 0.1 μM. CTA056 selectively targets malignant T cells and modulates oncomirs. CTA056 induces apoptosis and is a potential therapeutic agent for the research of T-cell leukemia and lymphoma .

HY-147327

N-Formylsarcolysine	Drug Metabolite	Cancer
N-Formylsarcolysine has antitumor activity, and inhibits leukemia by increasing the Hb and erythrocyte levels and decreasing the number of leukocytes. N-Formylsarcolysine also involves in glioblastoma and other diseases research .

HY-P992404

MDX-1401	TNF Receptor	Cancer
MDX-1401 is a fully human IgG1 (κ isotype) monoclonal antibody against CD30, with a K_d value of 0.83 nmol/L. MDX-1401 induces antibody-dependent cellular cytotoxicity in CD30-expressing cells and inhibits tumor growth in CD30 ⁺ lymphoma xenograft models. MDX-1401 can be used in research related to malignant lymphoma and Hodgkin lymphoma .

HY-P991914

FTL004	CD38 Apoptosis	Cancer
FTL004 is an anti-CD38 monoclonal antibody. FTL004 exhibits enhanced Proapoptotic activity and displays stronger ADCC against CD38 ⁺ malignant cells. FTL004 can be used for the research of multiple myeloma and non-Hodgkin lymphoma[1].

HY-179399

β-carboline-ACS81	Apoptosis Mitochondrial Metabolism	Cancer
β-carboline-ACS81 is a β-carboline derivative with potent antitumor properties. β-carboline-ACS81 induces apoptosis through the collapse of mitochondrial membrane potential and arrests cell cycle at G2/M phase in HL-60 cells. β-carboline-ACS81 possesses potent antiproliferative activity against HL-60 cells (IC₅₀ = 1.52 μM). β-carboline-ACS81 can be used for the research of leukemia, histiocytic lymphoma, hepatocellular carcinoma, malignant melanoma, colorectal carcinoma and lung carcinoma .

HY-W017194S2

2-Phenylbutanoic acid-d3	Isotope-Labeled Compounds	Others
2-Phenylbutanoic acid-d₃ is the deuterium labeled 2-Phenylbutanoic acid (HY-W017194). 2-Phenylbutanoic acid is a monocarboxylic acid. 2-Phenylbutanoic acid interacts with proteins. 2-Phenylbutanoic acid is used in the study of malignant lymphoma and HIV virus-related diseases.

HY-N7917

Tenacigenoside A	P-glycoprotein Apoptosis Bcl-2 Family	Cancer
Tenacigenoside A is a multidrug resistance reversal agent and apoptosis inducer that selectively acts on P-glycoprotein and apoptosis-related proteins (BCL2, BCL-XL, BID). Tenacigenoside A exerts its key activity by regulating the expression of apoptosis-related proteins and inhibiting P-gp function, thereby inhibiting tumor cell proliferation, inducing tumor cell apoptosis, and reversing multidrug resistance in tumors. Tenacigenoside A can be used in research on malignant tumors such as lymphoma .

HY-180956

PROTAC ALK degrader-5	PROTACs Anaplastic lymphoma kinase (ALK) STAT	Cancer
PROTAC ALK degrader-5 (Compound 17) is an efficient ALK PROTAC degrader, with its inhibitory effects on EML4-ALK and NPM-ALK being 27.4 nM and 116.5 nM respectively. PROTAC ALK degrader-5 exhibits potent anti-proliferative activity against H3122 and Karpas 299. PROTAC ALK degrader-5 effectively inhibits the phosphorylation of ALK and STAT3. PROTAC ALK degrader-5 can be used for the study of ALK-driven malignant tumors, such as human non-small cell lung cancer and anaplastic large cell lymphoma .

HY-P11280A

PRAME peptide (425-433) acetate	Melanocortin Receptor	Cancer
PRAME peptide (425-433) acetate is a proteasome-degraded peptide derived from the cancer-testis antigen PRAME (Preferentially Expressed Antigen in Melanoma). PRAME peptide (425-433) acetate is restricted by HLA-A02:01 and can serve as a target for bispecific T cell engager therapy in the context of major histocompatibility complex I presentation. PRAME peptide (425-433) acetate shows application potential in various malignant* tumors and is widely suitable for research related to solid tumors, melanoma, ovarian cancer, endometrial cancer, and lung cancer (including lung adenocarcinoma and lung squamous cell carcinoma). PRAME peptide (425-433) acetate can be used to explore disease of triple-negative breast cancer, diffuse large B-cell lymphoma, and head and neck squamous cell carcinoma .

Cat. No.	Product Name

HY-L171

Anti-Hematopathy Compound Library	4,172 compounds
Hematopathy, also known as hematopoietic system diseases, are a class of diseases that hematopoietic system has abnormal changes. Common hematopathy include: aplastic anemia, myeloproliferative diseases, thalassemia, leukemia, lymphoma, myeloma and hemophilia, etc. In recent years, treatments for hematopathy have been developed. In particular, the treatment of malignant hematopathy developed from chemotherapy, radiotherapy, bone marrow development to immunotherapy, induced differentiation therapy, cell therapy, gene therapy and hematopoietic stem cell transplantation. Although these therapies have greatly improved the survival rate of patients, there are still problems such as low cure rate and easy recurrence in the treatment of hematopathy. Therefore, it is of great significance to actively search for new hematopathy therapeutic drugs. MCE designs a unique collection of 4,172 anti-hematopathy small molecules, which is an effective tool for development and research of anti-hematopathy compounds.

Anti-Hematopathy Compound Library

4,172 compounds

Hematopathy, also known as hematopoietic system diseases, are a class of diseases that hematopoietic system has abnormal changes. Common hematopathy include: aplastic anemia, myeloproliferative diseases, thalassemia, leukemia, lymphoma, myeloma and hemophilia, etc. In recent years, treatments for hematopathy have been developed. In particular, the treatment of malignant hematopathy developed from chemotherapy, radiotherapy, bone marrow development to immunotherapy, induced differentiation therapy, cell therapy, gene therapy and hematopoietic stem cell transplantation. Although these therapies have greatly improved the survival rate of patients, there are still problems such as low cure rate and easy recurrence in the treatment of hematopathy. Therefore, it is of great significance to actively search for new hematopathy therapeutic drugs.

MCE designs a unique collection of 4,172 anti-hematopathy small molecules, which is an effective tool for development and research of anti-hematopathy compounds.

HY-L079

Anti-Blood Cancer Compound Library	4,121 compounds
Blood cancers, also called hematologic cancers, occur when abnormal blood cells start growing out of control, interrupting the function of normal blood cells, which fight off infection and produce new blood cells. Most blood cancers start in the bone marrow, which is where blood is produced. There are three main types of blood cancers: leukemia, lymphoma and myeloma, which afflict millions of children and adults every year, and are often deadly. Some common blood cancer treatments include stem cell transplantation, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. As we begin to understand the key signaling pathways and molecular drivers of malignant transformation in haematological disorders, new treatment strategies will continue to be developed. MCE offers a unique collection of 4,121 compounds with identified and potential anti-blood cancer activity. These compounds target blood cancer’s major targets and signaling pathways. MCE anti-blood cancer compound library is a useful tool for anti-blood cancer drugs screening and other related research.

Anti-Blood Cancer Compound Library

4,121 compounds

Blood cancers, also called hematologic cancers, occur when abnormal blood cells start growing out of control, interrupting the function of normal blood cells, which fight off infection and produce new blood cells. Most blood cancers start in the bone marrow, which is where blood is produced. There are three main types of blood cancers: leukemia, lymphoma and myeloma, which afflict millions of children and adults every year, and are often deadly.

Some common blood cancer treatments include stem cell transplantation, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. As we begin to understand the key signaling pathways and molecular drivers of malignant transformation in haematological disorders, new treatment strategies will continue to be developed.

MCE offers a unique collection of 4,121 compounds with identified and potential anti-blood cancer activity. These compounds target blood cancer’s major targets and signaling pathways. MCE anti-blood cancer compound library is a useful tool for anti-blood cancer drugs screening and other related research.

Cat. No.	Product Name	Target	Research Area